semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.083-999.0,  Pulmonary Arterial Hypertension of Congenital Heart Disease The patient has a congenital heart disease other than patent foramen ovale The diagnosis of pulmonary hypertension was confirmed by cardiac catheterization. Only patients with Eisenmenger syndrome can be included without catheterization The catheterization was done after 1 January 2009 A mean pulmonary artery pressure > 25 mm Hg Pulmonary vascular resistances > 3 piece Wood m2 Pulmonary capillary pressure available Consent for in the study must be signed by parents or legal guardians for minors, by the patient for adults The patient he had a surgical procedure or interventional catheterization cardiac catheterization between his diagnosis and in the observatory? If yes, it can only be included if a new catheterization confirmed the persistence of HTAP at least 6 months after the procedure Patient follow-up (at least once a year) in the center for its HTAP associated with congenital heart disease its
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Prostate Cancer For biochemical relapse after primary treatment 1. PSA > 0.2 ng/ml after radical prostatectomy confirmed at that level or higher on a subsequent test 3 months later 2. PSA increase >2 ng/ml from nadir following radiation therapy 3. PSA increase >2 ng/ml from nadir following radiation therapy plus androgen deprivation therapy with nadir defined with normalized testosterone level 4. Two consecutive PSA increases from nadir level after androgen blockade or androgen suppression therapy 2. Kidney function with GFR > 60 mL/sec/1.73m2 and Creatinine < 1.7mg, collected within 90 days of planned scan 1. if GFR is > or equal to 60 mL/sec/1.73m2, PET/CT will be completed with contrast 2. if GFR is < 60 mL/sec/1.73m2, PET/CT will be completed without contrast 3. if Creatinine is > than 1.7 mg, Radiology will follow ACR recommendations as outlined in department policy. 3. No known allergy to iodinated radiologic contrast media 4. Able to have MRI based on screening evaluation. If patient is found to be MRI incompatible, the 11C-choline PET/MRI portion of the study will not be completed. Please see the provided contact numbers for further options. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2  ECOG Performance Status > 2. 2. Concurrent malignancy, i.e. colon cancer. 3. Treatment for another malignancy except superficial skin cancer within 5 years
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly patients with active acromegaly on regular use of a stable dose of Octreotide-LAR and/or cabergoline for at least one year Insulin like growth factor 1 above the reference range during the last year of follow-up and testosterone levels within or below the third inferior tertile of normality  radiotherapy in the last 10 years, previous venous embolism (including family members) previous prostatic cancer or symptomatic benign hypertrophy triglyceride levels above 400 mg/dL renal failure defined by estimative of renal filtration below 30 ml/min liver disease defined by hepatic enzymes 3 times above normal limit active oncologic disease in the last 10 years and previous cardiac or cerebrovascular disease
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Female Infertility Due to Diminished Ovarian Reserve Menopausal Syndrome Sexual Function and Fertility Disorders Cardiovascular Diseases Karnofsky Performance Statue ≥ 70 WBC > 3,000/mm³ Hb > 9.0g/dl Platelet > 100,000 /mm³ SGOT/SGPT < 60 IU/L T-Bil < 1.5 mg/dL Cr < 1.2 mg/dL PaO2 > 80 torr normal ECG Written informed consent  Patients without information clinical risk factors Patients who have active infection
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Subject, man or woman, whose age is greater than or equal to 18 years Subject has a combination of defined values plus Insulin Like Growth Factor-1 and no braking growth hormone (<1.2 milli-International unit/L) during an oral glucose tolerance acromegaly Exposed: Subject with a surgically treated in remission with or without drug treatment somatostatinergic, acromegaly who received treatment with Gamma Knife radiosurgery within not less than 10 years and less than or equal to 20 years Not exposed: Subject with a surgically treated acromegaly controlled by treatment somatostatinergic, not having received Gamma Knife radiosurgery Subjects with thyroid under standardized assessment Levothyrox® in case of deficit associated thyroid stimulating Topic supported in a project partner services Subjects who have signed a written informed consent and agreeing to abide by the instructions of the protocol  Minor or over the age of 75 years subject Subjects with acromegaly resistant to somatostatinergic, or that required power is pegvisomant or cabergoline Subjects who received two pituitary neurosurgical treatment or treatment with conventional radiotherapy or radiosurgery treatments 2 Pregnant or lactating woman Topic is not affiliated with the social security system, or private about freedom Subject refusing to participate in the study or not signing the informed consent Subject with malignant disease known evolutionary
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Pituitary Tumor Pain Adult patient undergoing ENTS surgery for resection of pituitary tumor Adults >18 years and <80 years of age English speaking and literate or able to understand the use of a pain scale Body Mass Index >19 and <40 kg/m2  Renal failure (acute or chronic) or creatinine >2.0 Allergy or intolerance to acetaminophen, ibuprofen, or opioids Pre-operative opioid tolerance, dependence, or abuse Anaphylaxis to opioids History of peptic ulcer disease or recent gastrointestinal bleed requiring surgery Cirrhosis, hepatitis, liver transplant, or liver function studies out of normal range, defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin> 3x upper limit of normal range Subject unwilling or unable to sign informed consent for the study Pregnancy Incarcerated patients
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Written informed consent Male and female patients ≥18 years Patients with confirmed diagnosis of inadequately controlled acromegaly (mean GH concentration ≥1 μg/L and sex and age-adjusted IGF-1 >1.3 x ULN) Patients treated with octreotide LAR (30 mg or 40 mg) or lanreotide ATG (120 mg) monotherapy for at least 3 months prior to screening  Concomitant treatment with other medications reducing GH and or IGF-1, unless discontinued 3 months prior to screening Patients with compression of the optic chiasm requiring surgical intervention Diabetic patients with HbA1c >8% at screening Patients who are hypothyroid and not on adequate replacement therapy Patients with symptomatic cholelithiasis and acute or chronic pancreatitis Patients with clinically significant valvular disease Patients with risk factors for torsade de pointes (TdP) Hypokalaemia, hypomagnesaemia, uncontrolled hypothyroidism, family history of long QT syndrome or concomitant medications with known risk of TdP Patients with congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute MI less than one year prior to study entry or clinically significant impairment in cardiovascular function Concomitant disease(s) that could prolong the QT interval such as autonomic neuropathy (caused by diabetes or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Pituitary Adenoma Patients with suspected nonfunctioning pituitary macroadenomas (≥ 1 cm) with planned transsphenoidal surgery Adults (age 18-80 years) Medically stable for surgery Reasonable expectation that patient will complete study and be available for follow-up assessments  Prisoners Pregnant women Patients with suspected functioning pituitary adenoma Unable to obtain MRI of the pituitary (e.g., pacemaker, anaphylaxis to gadolinium, low GFR) Pituitary apoplexy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parathyroid Adenoma patients having parathyroid surgery for primary hyperparathyroidism from July 2009 to June 2016  age less than 18 years parathyroid carcinoma secondary or tertiary hyperparathyroidism
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Glioblastoma Written informed consent ≥18 years of age Prior resection of glioblastoma confirmed by histology Glioblastoma pretreated with standard radiotherapy without or with temozolomide First progression according to RANO First progression not within 3 months after completion of radiation therapy Complete removal of contrast-enhancing lesion considered feasible without significant risk of permanent speech or motor function according to MRI as confirmed by study committee after screening and prior to recruitment No encroachment of the M1 or A1 segments of the medial and anterior cerebral artery on MRI No contrast enhancement in presumed speech and primary motor areas on MRI No midline shift on MRI
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Pituitary Macroadenoma Adults 18-90 Pituitary macroadenoma ( >2.5 cm) in MRI Elect for transsphenoidal surgery  Children (age < 18) Pituitary macroadenoma Unable to tolerate MRI
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Adult patients with acromegaly treated for at least three months and no longer than three years with Lanreotide Autogel® 120 mg just before inclusion Patients capable of giving their informed consent to participate in the study and who agree to participate by signing the informed consent form  Active participation in any interventional or any other non-interventional acromegaly clinical study. (Previous participation in any interventional or any observational / post marketing study (PMS) of other somatostatin analogue should not be an criteria) Any medical or psychological condition, according to investigator judgement, that might compromise the ability to give informed consent
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Acromegaly Acromegalic patients undergoing surgery  None
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Tumours Naïve, unoperated pituitary tumour with GH or ACTH or TSH production or NFPA without treatment with somatostatin analogues or dopamine agonists  Patient who may not attend to the protocol according to the investigators opinion Pregnancy or lactating Isolated prolactin producing tumours Overproduction of gonadotrophins Carcinoids ie ectopic CRF production Known or suspected allergy to the trial product or related products
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Age 18 or older. 2. Patients diagnosed with acromegaly with GH-secreting pituitary adenoma on sellar MRI, meeting the biochemical outlined above (refer to 1. Diagnosis of acromegaly) and with typical acromegalic features. 3. No prior use of somatostatin analogues. 4. Adequate hepatic and renal function 5. Provision of a signed written informed consent  Severe co-morbid illness such as untreatable other malignancy and/or active infections. 2. Pregnant or lactating women 3. Hypersensitivity to Sandostatin or any component of the formulation
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acromegaly Subject has active acromegaly defined as elevated GH and IGF-1 levels (measured at a central laboratory) as outlined below A serum level for IGF-1 ≥1.3 x upper limit of normal range (ULN) during the screening period (applicable to both treatment naïve subjects and subjects who have stopped treatment and undergone a washout period prior to Visit 1(Week -4) Subjects must have mean serum GH concentration ≥2.5 μg/L in a GH cycle (5 samples taken at 0, 30, 60, 90 and 120 minutes) during the screening period The subject has undergone surgical removal of an adenoma for acromegaly at least 3 months prior to Screening, or is likely to require pituitary surgery in the future but not before completing at least 32 weeks of study treatment plus an additional follow up of 8 weeks for subjects taking part in the pharmacokinetics (PK) extension, or for whom pituitary surgery is not an option (due to contraindications, refusal etc.) and is therefore never likely to undergo pituitary surgery  The subject has been treated with radiotherapy within 10 years prior to Screening The subject has been treated with lanreotide Autogel, lanreotide PR, pegvisomant, cabergoline or octreotide LAR within 3 months of Screening or octreotide immediate release (IR) or bromocriptin within 2 weeks of Screening The subject has a history of or currently presents with clinically significant ventricular or atrial dysrhythmias ≥Grade 2, using the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) v4.0 The subject has uncontrolled diabetes (glycosylated haemoglobin (HbA1c) >8.5%)
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Neoplasms American Society of Anesthesiologists physical status I or II Pituitary tumour: non-functional macroadenoma, Rathke's cleft cyst, acromegaly Normal hypothalamic-pituitary-adrenal axis by hormone levels measurement previous to surgery  Cushing disease Pituitary apoplexy Craniopharyngioma Chronic corticosteroid use Hemodynamic instability Altered consciousness (Glasgow Coma Scale score less than 15) Atrioventricular block in any degree Preoperative bradycardia Alpha 2 agonist use (clonidine, alpha-methyldopa) Pregnancy or breast feeding
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bacterial Infection Due to Helicobacter Pylori (H. Pylori) Patients infected with Helicobacter pylori  Patients with gastric cancer or MALT lymphoma